The Boston CROI connection, page-21

I think you understand incorrectly.

Phase Two exploratory is about to be finally finalised with a paper and presentation of the 100mg dose cohort AND a hypothesis, backed by good science, as to how BIT225 works.

The PATHWAY to P3 is being investigated.

The pathway may well be P2B.

BUT, the new mode of action explanation and the paper and the new patents, MAY be enough for P3 studies. I sort of doubt it but they won't be letting us know for quite a while yet imho.

They've never said that P2 is finished and they've never said that P3 is the next step. You should be able to work out why. Maybe the results will help but I'm tipping its more to do with the FDA and pharma.


No word on the promised FDA talks promised last year.

Could be a good announcement in it from our SAB.